WA
NRIX icon

Wasatch Advisors’s Nurix Therapeutics NRIX Stock Holding History

Wasatch Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-313,889
Closed -$2.9M – 238
2025
Q3 		$2.9M Sell
313,889
-173,047
-36% -$1.8M 0.02% 209
2025
Q2 		$5.55M Sell
486,936
-82,861
-15% -$895K 0.03% 184
2025
Q1 		$6.77M Sell
569,797
-29,604
-5% -$495K 0.04% 170
2024
Q4 		$11.3M Sell
599,401
-108,976
-15% -$2.5M 0.06% 154
2024
Q3 		$15.9M Sell
708,377
-149,690
-17% -$3.39M 0.08% 136
2024
Q2 		$17.9M Sell
858,067
-378,686
-31% -$5.9M 0.1% 129
2024
Q1 		$18.2M Sell
1,236,753
-1,512,992
-55% -$16.3M 0.1% 140
2023
Q4 		$28.4M Sell
2,749,745
-814,871
-23% -$5.58M 0.16% 113
2023
Q3 		$28M Sell
3,564,616
-305,159
-8% -$2.79M 0.18% 110
2023
Q2 		$38.7M Buy
3,869,775
+695,773
+22% +$7.1M 0.23% 87
2023
Q1 		$28.2M Buy
3,174,002
+635,370
+25% +$6.62M 0.18% 107
2022
Q4 		$27.9M Sell
2,538,632
-118,805
-4% -$1.43M 0.19% 104
2022
Q3 		$34.6M Buy
2,657,437
+394,374
+17% +$6.24M 0.24% 96
2022
Q2 		$28.7M Buy
2,263,063
+716,374
+46% +$8.12M 0.18% 110
2022
Q1 		$21.7M Buy
1,546,689
+343,100
+29% +$6.09M 0.11% 150
2021
Q4 		$34.8M Buy
1,203,589
+31,932
+3% +$968K 0.14% 128
2021
Q3 		$35.1M Sell
1,171,657
-22,958
-2% -$708K 0.14% 133
2021
Q2 		$31.7M Buy
1,194,615
+158,914
+15% +$4.67M 0.13% 146
2021
Q1 		$32.2M Buy
+1,035,701
New +$39.2M 0.14% 127

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors's NRIX Position: Q4 2025 in Review

Wasatch Advisors sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 313,889 shares — an estimated $2.9M sold.

Wasatch Advisors first reported a position in NRIX in Q1 2021 and held it in 19 quarters. The position peaked at $38.7M in Q2 2023. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Wasatch Advisors reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wasatch Advisors sold 313,889 Nurix Therapeutics shares in Q4 2025, an estimated $2.9M.
  • Wasatch Advisors first reported a position in Nurix Therapeutics in Q1 2021 and held it in 19 quarters.
  • Wasatch Advisors's Nurix Therapeutics position peaked at $38.7M in Q2 2023.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Wasatch Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.